{"name":"Neuvosyn Laboratories, LLC","slug":"neuvosyn-laboratories-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"North Star","genericName":"North Star","slug":"north-star","indication":"Treatment of type 2 diabetes","status":"marketed"}]}],"pipeline":[{"name":"North Star","genericName":"North Star","slug":"north-star","phase":"marketed","mechanism":"North Star is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes","Reduction of major adverse cardiovascular events in adults with established cardiovascular disease or multiple cardiovascular risk factors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPb1hSRXYtSW1nQ2NXRHJCMURyazNmZGcwR0c0NjRJb1FRSGhiZE1YcHJCM3I1dV8zd1VOX3k1Smo2LTRQWGk2WHJtOU9VbEpCNzNCUTNWd3FuYWE2U3duQkExbUpVWDRMOHJXOURneVBlWHN1eXhnd3pxR01NaURCdjFXZHFybEZhaWNCaHVCR1Vkdi1EbEM1RFFGNUI5MmpOMExCVThuczYzckhVR09PNDlmOTZEblFLVW1OREVtdUdGQ2xCUF9ZU2VyZVhBUTE3dUprWGs1R1RPM1hIaWY3OHVoSWR4V2RVdlU4?oc=5","date":"2026-03-25","type":"regulatory","source":"PR Newswire","summary":"Acella Pharmaceuticals Thanks FDA for Maintaining Access to Desiccated Thyroid Extract (DTE) Products - PR Newswire","headline":"Acella Pharmaceuticals Thanks FDA for Maintaining Access to Desiccated Thyroid Extract (DTE) Products","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPMHYwWVVieF95RTMzTXoxdTJHdnZMSjRvYUVvUGtNeUs4OVR3czd5dGNEOHhMRjBsVkFNQnAxR0tMd1d5ZUJaRmtEclZMUmJ5ZklydE84d1JSVXViREJxLThMYjNyZlg4MG9CMDBlM29CQ25MUGRRbHpZalNnbktsSUZXTFZKUQ?oc=5","date":"2025-09-24","type":"trial","source":"PharmaTimes","summary":"North Star shows promise in phase 2 thyroid trial - PharmaTimes","headline":"North Star shows promise in phase 2 thyroid trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}